Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin.

Susanne Deininger; Peter Törzsök; David Oswald; Lukas Lusuardi

doi:10.3390/cancers13133206

Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin.

Susanne Deininger^* (Erstautor/-in), Peter Törzsök (Co-Autor/-in), David Oswald (Co-Autor/-in), Lukas Lusuardi (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinik für Urologie und Andrologie

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

8 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Cancers
Jahrgang	13
Ausgabenummer	13
DOIs	https://doi.org/10.3390/cancers13133206
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.3390/cancers13133206

Dieses zitieren

@article{4501098f414b460baa85124406217273,

title = "Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin.",

keywords = "TRANSITIONAL-CELL CARCINOMA, INVASIVE BLADDER-CANCER, COMPREHENSIVE MOLECULAR CHARACTERIZATION, PHASE-III TRIAL, SOLID TUMORS, ANDROGEN RECEPTOR, VINFLUNINE PLUS, SUPPORTIVE CARE, DOUBLE-BLIND, OPEN-LABEL",

author = "Susanne Deininger and Peter T{\"o}rzs{\"o}k and David Oswald and Lukas Lusuardi",

note = "all: Department of Urology and Andrology, Salzburg University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria",

year = "2021",

doi = "10.3390/cancers13133206",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "13",

}

Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. / Deininger, Susanne (Erstautor/-in); Törzsök, Peter (Co-Autor/-in); Oswald, David (Co-Autor/-in) et al.
in: Cancers, Jahrgang 13, Nr. 13, 2021.

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

TY - JOUR

T1 - Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin.

AU - Deininger, Susanne

AU - Törzsök, Peter

AU - Oswald, David

AU - Lusuardi, Lukas

N1 - all: Department of Urology and Andrology, Salzburg University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria

PY - 2021

Y1 - 2021

KW - TRANSITIONAL-CELL CARCINOMA

KW - INVASIVE BLADDER-CANCER

KW - COMPREHENSIVE MOLECULAR CHARACTERIZATION

KW - PHASE-III TRIAL

KW - SOLID TUMORS

KW - ANDROGEN RECEPTOR

KW - VINFLUNINE PLUS

KW - SUPPORTIVE CARE

KW - DOUBLE-BLIND

KW - OPEN-LABEL

U2 - 10.3390/cancers13133206

DO - 10.3390/cancers13133206

M3 - Review article

C2 - 34206980

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 13

ER -